|Full Name||v-rel reticuloendotheliosis viral oncogene homolog (avian)|
|Product Description||Goat polyclonal antibody to REL|
|Background||Proto-oncogene that may play a role in differentiation and lymphopoiesis. NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. The NF-kappa-B heterodimer RELA/p65-c-Rel is a transcriptional activator. |
|Synonyms||oncogene REL, avian reticuloendotheliosis, vrel reticuloendotheliosis viral oncogene homolog (avian), C-Rel proto-oncogene protein, vrel reticuloendotheliosis viral oncogene homolog, v-rel reticuloendothelios, CRel protooncogene protein, CRel, REL, vrel reticuloendothelios, v-rel reticuloendotheliosis viral oncogene homolog, C-Rel, C Rel, v rel reticuloendothelios, C Rel proto oncogene protein|
|Specificity||This antibody is specific for REL.|
|Predicted Cross Reactivity species Predicted cross-reactivity:|
Predicted cross-reactivity is based on sequence homology, with greater than 80% immunogen sequence identity considered positive.
Please note that we are only able to guarantee products to work in applications and species in which they have been tested.